Last edition
News about "Ulcerative Colitis (UC) treatment"
Eli Lilly and Company's Omvoh Shows 4-Year Disease Clearance in Ulcerative Colitis
Eli Lilly and Company’s Omvoh (mirikizumab-mrkz), the first IL-23p19 inhibitor, shows durable disease clearance in ulcerative colitis, with more than 60 percent of patients maintaining remission through 4 years in the LUCENT-3 study.
Ulcerative Colitis (UC) Treatment | 06/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members